SEC Filing Summary

On June 24, 2026, Centessa Pharmaceuticals plc (the "Company") was acquired by Eli Lilly and Company through its subsidiary LDH XV Corporation via a scheme of arrangement. As part of the transaction, all outstanding share options were cancelled and converted into the right to receive cash and contingent value rights (CVRs). Specifically, option holders received an amount in cash equal to the difference between $38.00 and the option's exercise price, plus one CVR per share, potentially worth up to an additional $9.00 per share upon achievement of specified milestones. No options were exercised prior to the acquisition. Brett I. W. Zbar, a director, had his share options cancelled. The reporting owner disclaims beneficial ownership except for any pecuniary interest.